Sarepta Therapeutics (SRPT) Common Equity (2010 - 2026)

Sarepta Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 31.71% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 31.71% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 25.34% from the prior year.
• Common Equity advanced to $1.5 billion in Q1 2026 per SRPT's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.5 billion in Q4 2024 and bottomed at $385.0 million in Q4 2022.
• The 5-year median for Common Equity is $961.2 million (2024), against an average of $984.1 million.
• Across the five-year window, Common Equity sank 58.52% in 2022 and jumped 123.23% in 2023, its largest moves.
• Year by year, Common Equity stood at $385.0 million in 2022, then surged by 123.23% to $859.3 million in 2023, then soared by 77.78% to $1.5 billion in 2024, then retreated by 25.34% to $1.1 billion in 2025, then jumped by 31.95% to $1.5 billion in 2026.
• Per Business Quant, the three latest SRPT Common Equity figures stand at $1.5 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.3 billion (Q3 2025).